Ibsa Drug Patent Portfolio
Ibsa owns 3 orange book drugs protected by 6 US patents Given below is the list of Ibsa's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11241382 | Administration regimen of compositions of T4 thyroid hormone with high oral absorption | 17 Sep, 2039 | Active |
US10537538 | High-stability packaged solutions of T4 thyroid hormone | 28 Feb, 2037 | Active |
US11096913 | High-stability packaged solutions of T4 thyroid hormone | 28 Feb, 2037 | Active |
US7691411 | Pharmaceutical formulae for thyroid hormones and procedures for obtaining them | 14 Mar, 2024 | Expired |
US7723390 | Pharmaceutical formulations for thyroid hormones | 14 Mar, 2024 | Expired |
US5607690 | External anti-inflammatory and analgesic plaster preparation | 13 Apr, 2014 | Expired |
Latest Legal Activities on Ibsa's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ibsa.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jun, 2023 | US10537538 |
Recordation of Patent Grant Mailed
Critical
| 08 Feb, 2022 | US11241382 |
Patent Issue Date Used in PTA Calculation
Critical
| 08 Feb, 2022 | US11241382 |
Email Notification
Critical
| 21 Jan, 2022 | US11241382 |
Issue Notification Mailed
Critical
| 19 Jan, 2022 | US11241382 |
Application Is Considered Ready for Issue
Critical
| 07 Jan, 2022 | US11241382 |
Dispatch to FDC | 07 Jan, 2022 | US11241382 |
Issue Fee Payment Verified
Critical
| 23 Dec, 2021 | US11241382 |
Issue Fee Payment Received
Critical
| 23 Dec, 2021 | US11241382 |
Mail Notice of Allowance
Critical
| 05 Nov, 2021 | US11241382 |
Electronic Review
Critical
| 05 Nov, 2021 | US11241382 |
Email Notification
Critical
| 05 Nov, 2021 | US11241382 |
Notice of Allowance Data Verification Completed
Critical
| 03 Nov, 2021 | US11241382 |
Payment of Maintenance Fee, 12th Year, Large Entity | 21 Oct, 2021 | US7723390 |
Information Disclosure Statement considered
Critical
| 15 Oct, 2021 | US11241382 |
Ibsa Drug Patents' Oppositions Filed in EPO
Ibsa drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 21, 2021, by Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.. This opposition was filed on patent number EP17794903A. Click below to reveal the latest opposition data.
Application | Filing Date | Opposition Party | Legal Status |
---|---|---|---|
EP17794903A | Apr, 2021 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Granted and Under Opposition |
Ibsa's Family Patents
Ibsa Drug List
Given below is the complete list of Ibsa's drugs and the patents protecting them.
1. Flector
Flector is protected by 1 patent, which has expired already. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US5607690 | External anti-inflammatory and analgesic plaster preparation |
13 Apr, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Flector's drug page
2. Tirosint
Tirosint is protected by 2 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US7691411 | Pharmaceutical formulae for thyroid hormones and procedures for obtaining them |
14 Mar, 2024
(8 months ago)
| Expired |
US7723390 | Pharmaceutical formulations for thyroid hormones |
14 Mar, 2024
(8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tirosint's drug page
3. Tirosint-sol
Tirosint-sol is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11241382 | Administration regimen of compositions of T4 thyroid hormone with high oral absorption |
17 Sep, 2039
(14 years from now)
| Active |
US10537538 | High-stability packaged solutions of T4 thyroid hormone |
28 Feb, 2037
(12 years from now)
| Active |
US11096913 | High-stability packaged solutions of T4 thyroid hormone |
28 Feb, 2037
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tirosint-sol's drug page